Brokerages forecast that Agenus Inc. (NASDAQ:AGEN) will post sales of $5.37 million for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Agenus’ earnings, with the lowest sales estimate coming in at $4.74 million and the highest estimate coming in at $6.00 million. Agenus reported sales of $4.45 million in the same quarter last year, which would suggest a positive year over year growth rate of 20.7%. The business is expected to announce its next quarterly earnings report on Thursday, October 26th.

According to Zacks, analysts expect that Agenus will report full year sales of $5.37 million for the current financial year, with estimates ranging from $40.89 million to $66.60 million. For the next financial year, analysts anticipate that the business will post sales of $29.45 million per share, with estimates ranging from $23.29 million to $35.60 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that that provide coverage for Agenus.

Agenus (NASDAQ:AGEN) last issued its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.32) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.36) by $0.04. Agenus had a negative return on equity of 37,577.49% and a negative net margin of 280.96%. The company had revenue of $4.21 million during the quarter, compared to analyst estimates of $6.66 million. During the same quarter in the previous year, the firm earned ($0.33) earnings per share. Agenus’s revenue was down 36.1% on a year-over-year basis.

Several research firms recently issued reports on AGEN. BidaskClub upgraded Agenus from a “hold” rating to a “buy” rating in a report on Monday, July 24th. ValuEngine upgraded Agenus from a “strong sell” rating to a “sell” rating in a report on Monday, July 24th. Jefferies Group LLC restated a “buy” rating and set a $7.00 price target on shares of Agenus in a report on Friday, August 4th. Finally, Zacks Investment Research upgraded Agenus from a “sell” rating to a “buy” rating and set a $4.50 price target for the company in a report on Wednesday, July 5th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and three have assigned a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $5.88.

ILLEGAL ACTIVITY NOTICE: “Agenus Inc. (AGEN) Expected to Announce Quarterly Sales of $5.37 Million” was posted by Watch List News and is owned by of Watch List News. If you are viewing this article on another domain, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this article can be accessed at https://www.watchlistnews.com/agenus-inc-agen-expected-to-announce-quarterly-sales-of-5-37-million/1581069.html.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company grew its holdings in Agenus by 6.7% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 63,595 shares of the biotechnology company’s stock valued at $248,000 after buying an additional 4,006 shares in the last quarter. Voya Investment Management LLC grew its holdings in Agenus by 18.5% during the 2nd quarter. Voya Investment Management LLC now owns 40,855 shares of the biotechnology company’s stock valued at $160,000 after buying an additional 6,381 shares in the last quarter. OxFORD Asset Management LLP purchased a new position in Agenus during the 2nd quarter valued at approximately $141,000. Vanguard Group Inc. grew its holdings in Agenus by 5.2% during the 2nd quarter. Vanguard Group Inc. now owns 3,530,585 shares of the biotechnology company’s stock valued at $13,805,000 after buying an additional 174,162 shares in the last quarter. Finally, Northern Trust Corp grew its holdings in Agenus by 4.1% during the 2nd quarter. Northern Trust Corp now owns 941,631 shares of the biotechnology company’s stock valued at $3,682,000 after buying an additional 37,239 shares in the last quarter. Institutional investors and hedge funds own 39.51% of the company’s stock.

Shares of Agenus (AGEN) remained flat at $4.10 on Tuesday. The stock had a trading volume of 330,634 shares. Agenus has a 12-month low of $3.20 and a 12-month high of $7.49. The stock’s market capitalization is $408.82 million. The firm has a 50 day moving average of $3.84 and a 200-day moving average of $3.85.

Agenus Company Profile

Agenus Inc (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body’s immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon).

Get a free copy of the Zacks research report on Agenus (AGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Agenus (NASDAQ:AGEN)

Receive News & Ratings for Agenus Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agenus Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.